Index of Veterinary Drugs
Functional Classes
Glossary

Adrenoceptor agonist

Clenbuterol

Species

Tissue

MRL

Year of Adoption

Note

Cattle

Fat

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Fat

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Fat

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Fat

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Kidney

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Kidney

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Kidney

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Kidney

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Liver

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Liver

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Liver

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Liver

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Milk

0.05 µg/l

2003

-

Species

Cattle

Tissue

Milk

MRL

0.05 µg/l

Year of Adoption

2003

Note

-

Cattle

Muscle

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Muscle

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Muscle

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Muscle

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Showing 1 to 9 of 9 entries